Kenvue Launches CEO Transition to Drive Growth

Kenvue, the world’s largest pure-play consumer health company, announced a leadership transition and an ongoing strategic review aimed at unlocking shareholder value and advancing the company’s long-term growth.

The company’s Board of Directors has appointed Kirk Perry as interim CEO, effective immediately. Perry, who joined Kenvue’s board in December 2024, brings over three decades of experience in consumer goods, technology, and business transformation. He replaces Thibaut Mongon, who has stepped down from his executive role and the board.

“The actions announced today are to ensure we have the right talent, brand portfolio and operational foundation to fully capitalize on Kenvue’s strengths,” said Larry Merlo, Chair of the Board, Kenvue. “We are aligning leadership expertise to drive the company forward.”

Perry’s appointment comes as the Board accelerates a comprehensive review of strategic alternatives for Kenvue, including potential adjustments to its brand portfolio and operating model. 

The Board’s Strategic Review Committee is working with Centerview Partners and McKinsey & Company to explore options that may simplify Kenvue’s structure and improve execution across its global operations. While no decisions have been finalized, the company plans to update shareholders as the process advances.

Kenvue also released select preliminary financial results for the second quarter ended June 29, 2025. Full results will be reported on Aug. 7, 2025 at which point the company will revise its full-year outlook.

Built on brands such as Aveeno, Neutrogena, Tylenol, Listerine, and BAND-AID, Kenvue continues to leverage its global platform and science-backed portfolio to compete in consumer health categories.